American College of Obstetricians and Gynecologists. Management of premenstrual disorders: ACOG clinical practice guideline no. 7. Obstet Gynecol. 2023;142(6):1516-1533.
Freeman EW, Halberstadt SM, Rickels K, et al. Core symptoms that discriminate premenstrual syndrome. J Womens Health (Larchmt). 2011;20(1):29-35.
Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, et al. Epidemiology of premenstrual syndrome (PMS)—a systematic review and meta-analysis study. J Clin Diagn Res. 2014;8(2):106-109.
Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry. 2012;169(5):465-475.
Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94(3):236-240.
Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2014.
Ismaili E, Walsh S, O'Brien PMS, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19(6):953-958.
Mortola JF, Girton L, Yen SS. Depressive episodes in premenstrual syndrome. Am J Obstet Gynecol. 1989;161(6 pt 1):1682-1687.
Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41-49.
Jespersen C, Lauritsen MP, Frokjaer VG, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database Syst Rev. 2024(8):CD001396.
Sepede G, Sarchione F, Matarazzo I, et al. Premenstrual dysphoric disorder without comorbid psychiatric conditions: a systematic review of therapeutic options. Clin Neuropharmacol. 2016;39(5):241-261.
de Wit AE, de Vries YA, de Boer MK, et al. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. Am J Obstet Gynecol. 2021;225(6):624-633.
Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008;111(5):1175-1182.
Reilly TJ, Wallman P, Clark I, et al. Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: a systematic review and meta-analysis of randomised trials. J Psychopharmacol. 2023;37(3):261-267.
Yonkers KA, Kornstein SG, Gueorguieva R, et al. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(10):1037-1044.
Ramos MG, Hara C, Rocha FL. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial. Int J Neuropsychopharmacol. 2009;12(8):1081-1088.
Naheed B, Kuiper JH, Uthman OA, et al. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database Syst Rev. 2017(3):CD010503.
Ma S, Song SJ. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2023(6):CD006586.
Carlini SV, Lanza di Scalea T, McNally ST, et al. Management of premenstrual dysphoric disorder: a scoping review. Int J Womens Health. 2022;14:1783-1801.
Wyatt KM, Dimmock PW, Ismail KMK, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111(6):585-593.
Kancheva Landolt N, Ivanov K. Short report: cognitive behavioral therapy—a primary mode for premenstrual syndrome management: systematic literature review. Psychol Health Med. 2021;26(10):1282-1293.
Hunter MS, Ussher JM, Browne SJ, et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol. 2002;23(3):193-199.
Siminiuc R, Ţurcanu D. Impact of nutritional diet therapy on premenstrual syndrome. Front Nutr. 2023;10:1079417.
Pearce E, Jolly K, Jones LL, et al. Exercise for premenstrual syndrome: a systematic review and meta-analysis of randomised controlled trials. BJGP Open. 2020;4(3) ): bjgpopen20X101032.
Verkaik S, Kamperman AM, van Westrhenen R, et al. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(2):150-166.
Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. Complement Ther Med. 2019;47:102190.
Khalesi ZB, Beiranvand SP, Bokaie M. Efficacy of chamomile in the treatment of premenstrual syndrome: a systematic review. J Pharmacopuncture. 2019;22(4):204-209.
Armour M, Ee CC, Hao J, et al. Acupuncture and acupressure for premenstrual syndrome. Cochrane Database Syst Rev. 2018(8):CD005290.
Comasco E, Kopp Kallner H, Bixo M, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. Am J Psychiatry. 2021;178(3):256-265.
Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011;84(8):918-924.
Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am Fam Physician. 2003;67(8):1743-1752.
Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician. 2002;66(7):1239-1249.
Daugherty JE. Treatment strategies for premenstrual syndrome. Am Fam Physician. 1998;58(1):183-192.